3.4 Vulnerable Populations & Additional Safeguards (Subparts B, C, D)

3.4 Vulnerable Populations & Additional Safeguards (Subparts B, C, D)

Under human subject protection regulations, vulnerability refers to a subject's susceptibility to coercion or undue influence, which compromises their ability to make a truly voluntary decision to participate in research.

• Coercion occurs when an overt threat of harm is presented by another person to obtain compliance (e.g., a physician telling a patient they will withdraw standard medical care if the patient does not join a trial).
• Undue influence occurs through an offer of an excessive, unwarranted, inappropriate, or improper reward or other overture in order to obtain compliance (e.g., offering a homeless individual $10,000 to participate in a high-risk phase I trial).

The Department of Health and Human Services (HHS) regulations under 45 CFR Part 46 establish specific subparts to protect vulnerable groups. The Food and Drug Administration (FDA) has matching regulations for children under 21 CFR Part 50 Subpart D, and handles other vulnerable populations through general Institutional Review Board (IRB) requirements under 21 CFR 56.111(a)(3) and 56.111(b).

Subpart B - Pregnant Women, Human Fetuses, and Neonates

Research involving pregnant women, human fetuses, and neonates is subject to strict requirements under HHS regulations (45 CFR 46 Subpart B) to ensure that the fetus is not exposed to unnecessary risk:

• Preclinical Data: Research may only be conducted if adequate preclinical studies on pregnant animals and clinical studies on non-pregnant women have been performed to assess potential maternal and fetal risk.
• Direct Benefit vs. Risk:
  • If the research holds out the prospect of direct benefit to the pregnant woman, or to both the woman and the fetus, the consent of the pregnant woman alone is sufficient.
  • If the research holds out the prospect of direct benefit solely to the fetus, the consent of both the pregnant woman and the father is required. The father's consent is not required if he is unavailable, incompetent, temporary incapacity exists, or the pregnancy resulted from rape or incest.
• Minimal Risk Standard: If the research holds out no prospect of direct benefit to the woman or the fetus, the risk to the fetus must be minimal, and the purpose of the study must be to obtain important biomedical knowledge that cannot be obtained by any other means.
• Neonates: Subpart B distinguishes between viable neonates (who are treated as children under Subpart D), nonviable neonates (who cannot be kept alive solely for research purposes), and neonates of uncertain viability. Research on neonates of uncertain viability requires the consent of both parents.

Subpart C - Prisoners

Prisoners are considered highly vulnerable because their incarceration severely restricts their freedom, making them susceptible to subtle coercion or undue influence.

• IRB Composition: When reviewing research involving prisoners, the IRB must include at least one member who is a prisoner or a prisoner representative (such as a prison chaplain, advocate, or social worker) who has the appropriate background to represent the prisoners' interests.
• OHRP Certification: The investigator must obtain approval from the Office for Human Research Protections (OHRP) before enrolling prisoners. The IRB must certify to OHRP that the study falls into one of the four permissible categories:
  1. Study of the possible causes, effects, and processes of incarceration, and of prison behavior.
  2. Study of prisons as institutional structures or of prisoners as incarcerated persons.
  3. Research on conditions particularly affecting prisoners as a class (e.g., vaccine trials, hepatitis, substance abuse), with OHRP approval.
  4. Research on practices which have the intent and reasonable probability of improving the health or well-being of the subject.
• Parole Decisions: The IRB must ensure that participation in research will have no effect on a prisoner's parole decisions, and this must be explicitly stated to the prisoner.

Subpart D - Children (21 CFR Part 50 Subpart D & 45 CFR Part 46 Subpart D)

Children are individuals who have not reached the legal age for consent to treatments or procedures involved in the research under the applicable law of the jurisdiction in which the research is conducted. Because they are legally unable to provide informed consent, a specific dual-authorization process is required: parental permission and child assent.

• Parental Permission: An investigator must obtain permission from the child's parents or guardians.
• Child Assent: Assent is a child's affirmative agreement to participate in research. The IRB determines whether child assent is required, taking into account the age, maturity, and psychological state of the children. Generally, assent is sought for children aged 7 and older.
• Categories of Pediatric Research:

• Wards of the State: Children who are wards of the state (e.g., in foster care) can only participate in Category 3 (50.53) or Category 4 (50.54) research if the study is related to their status as wards or is conducted in a school, camp, or institution where the majority of children are not wards. The IRB must appoint an advocate for each child who is a ward, independent of the research, investigator, and guardian.

Cognitively Impaired / Decisionally Impaired Adults

Adults with cognitive or decisional impairment (e.g., due to Alzheimer's disease, traumatic brain injury, schizophrenia, or acute drug intoxication) cannot provide legally effective informed consent.

• Legally Authorized Representative (LAR): The investigator must obtain consent from the subject's LAR. The definition and hierarchy of who can act as an LAR are defined by the laws of the state/local jurisdiction where the research is conducted.
• Capacity Assessment: The investigator must assess the prospective subject's capacity to consent. If a subject has fluctuating capacity, they should be assessed when they are most lucid. Standardized instruments like the Mini-Mental State Examination (MMSE) or the MacArthur Competence Assessment Tool may be used.
• Assent and Dissent: Even if an LAR provides consent, the investigator should obtain assent from the cognitively impaired subject if they are capable. If the subject dissents (refuses or resists), their refusal must be respected unless the investigational intervention holds out a prospect of direct benefit that is only available within the research setting.

Other Vulnerable Groups

• Employees and Students: These populations are vulnerable to subtle coercion due to real or perceived threats to their employment status, performance evaluations, or grades. IRB safeguards include requiring that recruitment be conducted by individuals not in a supervisory or grading relationship with the subjects, and explicitly stating that participation will not affect their jobs or grades.
• Economically or Educationally Disadvantaged: These individuals may be susceptible to undue influence if financial compensation is disproportionately high, leading them to overlook research risks. Compensation must be reasonable, prorated based on study visits (rather than back-loaded to the final visit), and consent documents must be written in simple, non-coercive lay language.